Myomo (MYO) Projected to Post Quarterly Earnings on Monday

Myomo (NYSEAMERICAN:MYO) is anticipated to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Myomo to post earnings of ($0.08) per share and revenue of $11.51 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Myomo (NYSEAMERICAN:MYO) last released its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $11.70 million during the quarter, compared to analysts’ expectations of $10.35 million. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. On average, analysts expect Myomo to post ($0.32) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Myomo Stock Performance

NYSEAMERICAN:MYO opened at $1.24 on Monday. The firm’s 50 day moving average is $1.42 and its two-hundred day moving average is $1.08. Myomo has a fifty-two week low of $0.60 and a fifty-two week high of $1.89. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The company has a market cap of $49.12 million, a P/E ratio of -3.65 and a beta of 1.74.

Insider Activity at Myomo

In other news, insider Harry Kovelman sold 17,250 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $1.73, for a total transaction of $29,842.50. Following the completion of the sale, the insider directly owned 105,983 shares in the company, valued at $183,350.59. This trade represents a 14.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 47,738 shares of company stock worth $70,662 over the last 90 days. Insiders own 12.14% of the company’s stock.

Myomo Company Profile

Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.

The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.